DE60322067D1 - Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus - Google Patents

Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus

Info

Publication number
DE60322067D1
DE60322067D1 DE60322067T DE60322067T DE60322067D1 DE 60322067 D1 DE60322067 D1 DE 60322067D1 DE 60322067 T DE60322067 T DE 60322067T DE 60322067 T DE60322067 T DE 60322067T DE 60322067 D1 DE60322067 D1 DE 60322067D1
Authority
DE
Germany
Prior art keywords
unrandeed
nightly
myoclonus
adenosine
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60322067T
Other languages
English (en)
Inventor
Hiroshi Kase
Naoki Seno
Akihisa Mori
Dayao Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60322067(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of DE60322067D1 publication Critical patent/DE60322067D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60322067T 2002-08-30 2003-08-27 Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus Expired - Lifetime DE60322067D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40695502P 2002-08-30 2002-08-30
PCT/US2003/026644 WO2004019949A1 (en) 2002-08-30 2003-08-27 Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders

Publications (1)

Publication Number Publication Date
DE60322067D1 true DE60322067D1 (de) 2008-08-21

Family

ID=31978389

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60322067T Expired - Lifetime DE60322067D1 (de) 2002-08-30 2003-08-27 Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus

Country Status (16)

Country Link
US (1) US7759355B2 (de)
EP (1) EP1534289B2 (de)
JP (1) JP4498140B2 (de)
KR (1) KR20050058468A (de)
CN (1) CN1671390A (de)
AR (1) AR041116A1 (de)
AT (1) ATE400275T1 (de)
AU (1) AU2003262860A1 (de)
BR (1) BR0313503A (de)
CA (1) CA2496920A1 (de)
DE (1) DE60322067D1 (de)
EA (1) EA008339B1 (de)
ES (1) ES2310258T5 (de)
MX (1) MXPA05001461A (de)
TW (1) TW200410698A (de)
WO (1) WO2004019949A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04007299A (es) * 2002-01-28 2004-10-29 Kyowa Hakko Kogyo Kk Metodos de tratamiento de pacientes que sufren de trastornos de movimiento.
DE60335294D1 (de) * 2002-12-19 2011-01-20 Schering Corp Dlung des extrapyramidalen syndroms
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20070149555A1 (en) * 2004-03-30 2007-06-28 Kyowa Hakko Kogyo Co., Ltd Prophylatic and/or therapeutic agents for chronic musculoskeletal pain
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
TW201102066A (en) * 2009-06-26 2011-01-16 Ferring Int Ct Sa Treatment of endometriosis
RU2480469C1 (ru) * 2012-02-03 2013-04-27 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") Замещенные 1,3-диэтил-8-винил-7-метил-3,7-дигидро-пурин-2,6-дионы-антагонисты аденозинового a2a рецептора и их применение
MY188541A (en) 2014-01-29 2021-12-21 Vyome Therapeutics Ltd Besifloxacin for the treatment of resistant acne
WO2022167778A1 (en) 2021-02-02 2022-08-11 Haiku Therapeutics Ltd Ebselen as adenosine receptor modulator

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
ATE265209T1 (de) 1996-07-17 2004-05-15 Merck & Co Inc Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten
US6001861A (en) 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
SE509618C2 (sv) 1997-03-06 1999-02-15 Goeran Blomqvist Farmaceutisk komposition för behandling av s k restless legs
EA002554B1 (ru) 1998-03-27 2002-06-27 Фармация Энд Апджон Компани Применение кабэрголина при лечении синдрома усталых ног
US20010029262A1 (en) 1998-06-29 2001-10-11 Sethi Kapil Dev Method of treatment or prophylaxis
US5945424A (en) 1998-07-31 1999-08-31 G & H Associates, Inc. Treatment of periodic limb movement syndrome
US6346283B1 (en) * 1999-03-26 2002-02-12 Ancile Pharmaceuticals Use of valeriana for the treatment of restless leg syndrome and related disorders
DE19938825A1 (de) 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
US6281207B1 (en) 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
US20010034320A1 (en) 2000-01-18 2001-10-25 Hans-Michael Brecht NK1-receptor antagonists for treating restless legs syndrome
WO2001062290A2 (en) * 2000-02-22 2001-08-30 Cellegy Canada Inc. Methods and compositions for improving sleep
US6258814B1 (en) 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
MXPA04007299A (es) 2002-01-28 2004-10-29 Kyowa Hakko Kogyo Kk Metodos de tratamiento de pacientes que sufren de trastornos de movimiento.
US20080176873A1 (en) * 2004-11-10 2008-07-24 Trinity Laboratories, Inc. Novel Pharmaceutical Compositions for Treating Acquired Chronic Pain and Associated Dysphoria

Also Published As

Publication number Publication date
CN1671390A (zh) 2005-09-21
TW200410698A (en) 2004-07-01
AU2003262860A1 (en) 2004-03-19
WO2004019949A1 (en) 2004-03-11
KR20050058468A (ko) 2005-06-16
JP2005539050A (ja) 2005-12-22
ES2310258T3 (es) 2009-01-01
CA2496920A1 (en) 2004-03-11
EA008339B1 (ru) 2007-04-27
AR041116A1 (es) 2005-05-04
ES2310258T5 (es) 2012-05-31
EP1534289A1 (de) 2005-06-01
US20050245545A1 (en) 2005-11-03
JP4498140B2 (ja) 2010-07-07
EP1534289B2 (de) 2012-02-22
MXPA05001461A (es) 2005-06-03
US7759355B2 (en) 2010-07-20
EA200500427A1 (ru) 2005-08-25
ATE400275T1 (de) 2008-07-15
BR0313503A (pt) 2005-06-21
EP1534289B1 (de) 2008-07-09

Similar Documents

Publication Publication Date Title
FR19C1072I2 (fr) Derive de 2-acylaminothiazole et son sel
ATE398455T1 (de) Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
ATE490775T1 (de) Verwendung von a2a rezeptor-antagonisten zur behandlung des extrapyramidalen syndroms
NO20044345L (no) NE- og 5-HT reopptakinhibitorer for behandling av viscerale smertesyndromer
ATE428424T1 (de) 1-benzoyl-piperazin-derivate als glycin- aufnahmehemmer zur behandlung von psychosen
HK1094203A1 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
DK1830869T3 (da) Fremgangsmåde til behandling eller profylakse
IS8119A (is) Þétt N-heteróhringlaga efnasambönd og notkun þeirra sem CRF viðtakamótlyfja
IL180371A0 (en) Method of treating sjogren's syndrome
NO20044148L (no) Sammensetning og fremgangsmate for bronnrensing
IL183709A0 (en) Compositions and methods for treating conditions of the nail unit
PT1569529E (pt) Melhoramentos relacionados com artigos para fumar
ITMI20050262A1 (it) Sostanze composizioni e metodi di trattamento dell'alopecia
IL175179A0 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
EP1907840A4 (de) Verfahren und vorrichtung zur aufrechterhaltung des effektiven betriebs einer vorrichtung zur durchleuchtung von vogeleiern
DE60322067D1 (de) Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus
GB0522460D0 (en) Composition and method for the treatment of avian influenza
ATE512967T1 (de) Als kinaseinhibitoren geeignete pyrrolotriazinverbindungen
ZA200802552B (en) Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
FI20041278A0 (fi) Menetelmä ja laittesto puun tai puutuotteiden käsittelemiseksi
WO2007045705A3 (es) Compuestos para el tratamiento de la fibrilación auricular
ZA200803236B (en) Adenosine A2a receptor antagonists for the treatment of Extra-Pyramidal syndrome and other movement disorders
EP1660010A4 (de) Zusammensetzungen und verfahren zur wiederherstellung der empfänglichkeit für eine behandlung mit her2-antagonisten
DE60327856D1 (de) Zusammensetzungen und verfahren zur hautbräunung
DE602004021143D1 (de) Vorrichtung und verfahren zum erhalten von verzögerungs-diversity

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: KYOWA HAKKO KIRIN CO., LTD., TOKYO, JP